Specifically, the authors identify a gene fusion, CARD11–PIK3R3, which enhances CARD11‐BCL10‐MALT1 (CBM) complex signaling, cytokine production, and anti‐tumor efficacy of therapeutic T cells in immunotherapy‐refractory models. This evidence concerns the gene CARD11 and neoplasm.